Catalent flags problems at its manufacturing plants; CFO departs
(Reuters) – Contract drug manufacturer Catalent Inc on Friday warned that slow production at three of its facilities will impact its fiscal 2023 results and said CFO Thomas Castellano has stepped down, sending its shares down more than 20%. The company said it experienced “productivity issues” at its gene therapy manufacturing site in Harmans, Maryland …
Catalent flags problems at its manufacturing plants; CFO departs Read More »